New Products In Brief

Recent product approvals and launches

Torax Medical Inc.’s Linx reflux management system for treating gastroesophageal reflux disease (GERD) has gained PMA approval, FDA announced March 22. GERD is a chronic condition in which food or liquid in the stomach flows back into the esophagus. Linx is surgically implanted at the lower esophageal sphincter to keep it closed and prevent the backward flow of stomach contents. The device, which is composed of a ring-shaped, magnetized series of titanium beads, is approved for GERD patients who continue to have symptoms despite the use of maximum medical therapy for reflux. In January, FDA’s Gastroenterology and Urology Devices panel voted 9-0 that the device’s benefits outweigh the risks for treating GERD, despite concerns that the firm’s 100-patient pivotal study missed its primary efficacy endpoint and lacked a control group. (See [A#01120116017].) As a condition of approval, Shoreview, Minn.-based Torax will institute a training program to educate new users on patient selection, device implantation and post-procedural care, FDA noted.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Dexcom Wins FDA Nod For 15-Day G7 CGM, Closing Gap With Abbott’s 14-Day FreeStyle Libre

 
• By 

Dexcom announced it received US clearance for its 15-day CGM, which has a MARD of 8.0% and is expected to launch in the second half of 2025 to allow for integration with insulin pumps.

Diagnostics Are Essential, But How Can Companies Ensure A Fair Price?

 

Biotech and pharma are increasingly clear about one thing: They need diagnostics. But with prices suppressed, how have diagnostics companies proven their utility without going under?

EU Harmonized Standards Continue To Trickle In Under MDR

 

Well over 200 European standards need harmonizing under the MDR. But only around 12% have been attended to so far.